📊 ADIL Key Takeaways
Is Adial Pharmaceuticals, Inc.. (ADIL) a Good Investment?
ADIL is a pre-revenue pharmaceutical company burning approximately $1.6M annually in operating cash flow with a finite runway of 2-3 years based on current cash reserves. While balance sheet metrics show strong liquidity (3.18x current ratio) and zero debt, the absence of any revenue generation and ongoing cash burn represent existential business risks typical of early-stage biotech companies with unproven commercial viability.
ADIAL appears to be a pre-revenue biotech with no current operating income base, persistent losses, and negative free cash flow. While the balance sheet is relatively clean with high cash, low liabilities, and no long-term debt, the current cash balance does not comfortably cover the recent annual cash burn, which raises funding and dilution risk. Losses have improved year over year, but the improvement is not yet supported by commercial revenue or proven operating leverage.
Adial Pharmaceuticals, Inc.. Key Strengths (ADIL)
- Strong liquidity position with $4.6M cash representing 88% of total assets
- Improved net loss and EPS by 39.6% and 82.5% YoY, indicating expense management
- Zero debt burden eliminates financing risk from leverage
- Strong liquidity with $5.88M in cash and 4.42x current and quick ratios
- No meaningful debt burden, reducing solvency pressure
- Net loss and diluted EPS improved materially year over year
ADIL Stock Risks: Adial Pharmaceuticals, Inc.. Investment Risks
- Zero revenue with no evidence of commercialization or customer traction
- Negative operating cash flow of -$1.6M annually with finite 2.9-year cash runway
- High pharmaceutical development risk: clinical trials may fail, FDA approval uncertain
- Negative ROE (-54.4%) and ROA (-38.7%) indicating asset destruction
- No identifiable milestone achievements or pipeline progress data disclosed
- No revenue base, making the business entirely dependent on external financing and pipeline progress
- Negative operating cash flow and free cash flow imply limited cash runway
- Very weak profitability metrics including deeply negative ROE and ROA signal poor capital efficiency
Key Metrics to Watch
- Quarterly revenue generation (first dollar of sales)
- Operating cash flow trend and monthly cash burn rate
- Cash balance and projected runway remaining
- Clinical trial progression, FDA interactions, regulatory approvals
- Changes in shares outstanding and dilution from future financing
- Quarterly operating cash burn relative to cash on hand
- Progress toward revenue generation or late-stage clinical/regulatory milestones
Adial Pharmaceuticals, Inc.. (ADIL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.18x current ratio provides a solid financial cushion.
ADIL Profit Margin, ROE & Profitability Analysis
ADIL vs Healthcare Sector: How Adial Pharmaceuticals, Inc.. Compares
How Adial Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Adial Pharmaceuticals, Inc.. Stock Overvalued? ADIL Valuation Analysis 2026
Based on fundamental analysis, Adial Pharmaceuticals, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Adial Pharmaceuticals, Inc.. Balance Sheet: ADIL Debt, Cash & Liquidity
ADIL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Adial Pharmaceuticals, Inc..'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-68.01 indicates the company is currently unprofitable.
ADIL Revenue Growth, EPS Growth & YoY Performance
Adial Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
ADIL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Adial Pharmaceuticals, Inc.. (CIK: 0001513525)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ADIL
What is the AI rating for ADIL?
Adial Pharmaceuticals, Inc.. (ADIL) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ADIL's key strengths?
Claude: Strong liquidity position with $4.6M cash representing 88% of total assets. Improved net loss and EPS by 39.6% and 82.5% YoY, indicating expense management. ChatGPT: Strong liquidity with $5.88M in cash and 4.42x current and quick ratios. No meaningful debt burden, reducing solvency pressure.
What are the risks of investing in ADIL?
Claude: Zero revenue with no evidence of commercialization or customer traction. Negative operating cash flow of -$1.6M annually with finite 2.9-year cash runway. ChatGPT: No revenue base, making the business entirely dependent on external financing and pipeline progress. Negative operating cash flow and free cash flow imply limited cash runway.
What is ADIL's revenue and growth?
Adial Pharmaceuticals, Inc.. reported revenue of N/A.
Does ADIL pay dividends?
Adial Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find ADIL SEC filings?
Official SEC filings for Adial Pharmaceuticals, Inc.. (CIK: 0001513525) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ADIL's EPS?
Adial Pharmaceuticals, Inc.. has a diluted EPS of $-1.48.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ADIL's fundamental grade?
Based on our AI fundamental analysis in June 2026, Adial Pharmaceuticals, Inc.. has a C grade with 84% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ADIL stock overvalued or undervalued?
Valuation metrics for ADIL: ROE of -54.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ADIL's AI grade for 2026?
Our dual AI analysis gives Adial Pharmaceuticals, Inc.. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ADIL's free cash flow?
Adial Pharmaceuticals, Inc..'s operating cash flow is $-1.6M, with capital expenditures of $64.6K.
How does ADIL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -54.4% (avg: 15%), current ratio 3.18 (avg: 2).